ArticleDrug safety2018
Challenges and Opportunities for the Traceability of (Biological) Medicinal Products.
Article in Drug safety, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The impact of global falsified medicines regulation on healthcare stakeholders in the legitimate pharmaceutical supply chain: a systematic review.Frontiers in medicine · 2024Pooled it
- Comprehensive promotion of drug traceability codes in China in 2025: challenges and solutions for tertiary outpatient pharmacists.Frontiers in pharmacology · 2025Article
- Blind-Watermarking-Proof-of-Concept of a Novel Approach to Ensure Batch Traceability for 3D Printed Tablets.Pharmaceutics · 2022Article
- Critical Success Factors and Traceability Technologies for Establishing a Safe Pharmaceutical Supply Chain.Methods and protocols · 2021Review
- Identifiability of Biologicals: An Analysis Using EudraVigilance, the European Union's Database of Reports of Suspected Adverse Drug Reactions.Clinical pharmacology and therapeutics · 2021Article
- Evaluation of Self-Care Activities and Quality of Life in Patients With Type 2 Diabetes Mellitus Treated With Metformin Using the 2D Matrix Code of Outer Drug Packages as Patient Identifier: Protocol for the DePRO Proof-of-Concept Observational Study.JMIR research protocols · 2021Article
- What Makes a National Pharmaceutical Track and Trace System Succeed? Lessons From Turkey.Global health, science and practice · 2020Article
- An integrated spectroscopic strategy to trace the geographical origins of emblic medicines: Application for the quality assessment of natural medicines.Journal of pharmaceutical analysis · 2020Article
- Article
- Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis.Drug safety · 2019Review
- Integration of a Commercial Barcode-Assisted Medication Dispensing System in a Teaching Hospital.Applied clinical informatics · 2019Article
- Identifiability of Biologicals in Adverse Drug Reaction Reports Received From European Clinical Practice.Clinical pharmacology and therapeutics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article provides an overview of the current situation regarding the traceability of medicinal products, with a focus on drug safety and biologics. Limited traceability of biologics, in particular with regard to the batch number, is associated with incomplete recording of exposure information in clinical practice. The current pharmaceutical barcode standards in the EU do not support the automatic recording of dynamic product information, such as batch numbers and expiry dates, by means of electronic barcode scanning in clinical practice. New barcode requirements, such as the 2D DataMatrix with encoded batch numbers and expiry dates, provided on both the primary and the secondary package, can facilitate routine barcode scanning at all points in the supply chain in different healthcare settings. To build a full track-and-trace system for medicines with electronic capture of relevant exposure information, alignment with other topics, such as the Falsified Medicines Directive and initiatives to reduce medication errors, is needed to increase the buy-in from all stakeholders and to solve multiple issues with a joint effort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.